Therapy Areas: Oncology
ImmPACT Bio USA names new chief financial officer and head of business development
10 August 2022 -

ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, announced on Tuesday that it has named Vikram Lamba, MBM as its new chief financial officer (CFO) and head of business development.

Lamba is to replace Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.

The company said that Lamba is a seasoned healthcare executive with deep and extensive global industry experience across various pharmaceutical and biotechnology organisations in the areas of management, M&A, finance, corporate development, and strategic alliances. He has served as CFO of ChromaCode, Inc, CFO of Civica, Inc, CFO and chief operating officer of Fortuna Fix, CEO and member of the board of directors of Zosano Pharma Corporation and CFO and chief business officer of Predictive Biosciences, Inc. He has served as vice president (VP) of corporate development at Advanced Medical Optics, Inc and CFO and VP of finance at GeneOhm Sciences, Inc. He has over 16 years of global experience in various positions at Bayer AG, where he was a Division CFO, and Burmah Castrol PLC.